Highest-materiality recent filing
DiaMedica Q1 net loss $10M; cash $51.3M; ReMEDy2 >70% enrollment
Net loss $10.0M in Q1 2026 vs $7.7M in Q1 2025; R&D expenses up to $8.0M from $5.7M.
DiaMedica reports FY2025 cash $59.9M; ReMEDy2 trial nearing 70% interim enrollment
Cash and investments $59.9M at Dec 31, 2025, up from $44.1M; runway through 2H 2027.
DiaMedica raises $12.2M via block sale of 1.5M shares at $8.10 under ATM
Sold 1,501,000 common shares to a healthcare institution fund on Dec 19, 2025.
FDA requested one non-clinical 10-day rabbit EFD/PPND study; results expected by Q2 2026.
Phase 2 Part 1a interim data (n=28) showed statistically significant reductions in blood pressure and uterine artery pulsatility index with no placental transfer of DM199.
DiaMedica enters $100M ATM equity distribution agreement with TD Cowen
Up to $100M in common shares may be sold through TD Cowen as sales agent.
DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor
Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.
DiaMedica raises $30.1M via private placement of 8.6M shares at $3.50 to fund preeclampsia pipeline
Private placement of 8,606,426 common shares at $3.50 per share, raising $30.1M gross proceeds.
DiaMedica reports positive Phase 2 preeclampsia data: BP reductions, no placental transfer
DM199 highest dose (Cohort 9, n=3): SBP -35 mmHg (p<0.05), DBP -15 mmHg (p<0.05) at 5 min post-infusion.
DiaMedica reports Q1 net loss $7.7M; preeclampsia Phase 2 topline data expected June-July 2025
Net loss $7.7M ($0.18/sh) vs $5.2M ($0.14) in Q1 2024; R&D expense rose to $5.7M on trial expansion.
DiaMedica FY2024 net loss $24.4M; cash $44.1M; preeclampsia data Q2 2025
Net loss $24.4M ($0.60/sh) vs $19.4M; R&D $19.1M, G&A $7.6M; no revenue.
DiaMedica updates AIS trial protocol, delays interim readout to Q4 2025; Q3 R&D spend rises
Expanded ReMEDy2 trial to include thrombolytic non-responders; interim analysis sample size increased to 200 from 144.
DiaMedica Expands DM199 into Preeclampsia with Phase 2 Trial Starting Q4 2024
Phase 2 open-label, single-arm, investigator-sponsored trial enrolling up to 120 preeclampsia/FGR patients; first subject Q4 2024, topline results H1 2025.
DiaMedica raises $11.8M in private placement at $2.50/share; funds stroke and preeclampsia trials
Gross proceeds $11.8M from sale of 4.72M shares at $2.50/share; expected close June 28, 2024.
DiaMedica dosed first patient in ReMEDy2 stroke trial; Q1 cash $46.5M
First participant enrolled in relaunched ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke.
DiaMedica FY2023: $52.9M cash, ReMEDy2 interim enrollment Q1 2025, CMO hired
Cash and investments $52.9M at Dec 31, 2023, up from $33.5M; net cash used in ops $18.7M.
On February 28, 2025, Richard Pilnik, who has been a member of the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), for over 15 years, informed the Company of his decision to retire and not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”).
On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.
Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. (“DiaMedica”), effective as of April 18, 2024, for personal reasons.
Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica’s Vice President of Clinical Operations, will assume leadership of DiaMedica’s clinical operations.
Max materiality 0.85 · Median 0.65 · Most common event other_material